ReviewSensors (Basel, Switzerland)2013
Aptamers as theranostic agents: modifications, serum stability and functionalisation.
Review in Sensors (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics.Materials today. Bio · 2025Review
- Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers.Molecular therapy. Nucleic acids · 2025Review
- Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy.Clinical and experimental medicine · 2025Review
- DNAzyme-based colorimetric biosensor for rapid detection of Shigella flexneri.Scientific reports · 2025Article
- The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy.Pharmaceutics · 2025Review
- Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025Review
- Novel Aptamer Strategies in Combating Bacterial Infections: From Diagnostics to Therapeutics.Pharmaceutics · 2024Review
- Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.Scientific reports · 2024Article
- Aptamers Targeting Membrane Proteins for Sensor and Diagnostic Applications.Molecules (Basel, Switzerland) · 2023Review
- In vitro selection of aptamers and their applications.Nature reviews. Methods primers · 2023Article
- Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.Cancer cell international · 2022Review
- The Ability of Nuclease-Resistant RNA Aptamer againstMolecules (Basel, Switzerland) · 2022Article
- Selection of RNA aptamers targeting hypoxia in cancer.Frontiers in molecular biosciences · 2022Article
- Aptamers: Cutting edge of cancer therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care.Diagnostics (Basel, Switzerland) · 2021Review
- Aptamers isolated against mosquito-borne pathogens.World journal of microbiology & biotechnology · 2021Review
- Review
- Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers, and the selection process known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) used to generate them, were first described more than twenty years ago. Since then, there have been numerous modifications to the selection procedures. This review discusses the use of modified bases as a means of enhancing serum stability and producing effective therapeutic tools, as well as functionalising these nucleic acids to be used as potential diagnostic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.